Schneider H J, Rovere S, Corneli G, Croce C G, Gasco V, Rudà R, Grottoli S, Stalla G K, Soffietti R, Ghigo E, Aimaretti G
Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Turin, Italy.
Eur J Endocrinol. 2006 Oct;155(4):559-66. doi: 10.1530/eje.1.02272.
Hypopituitarism frequently follows pituitary neurosurgery (NS) and/or irradiation. However, the frequency of hypothalamic-pituitary dysfunction after NS of non-pituitary intracranial tumors is unclear. The aim of this study was to assess the presence of endocrine alterations in patients operated on for intracranial tumors.
This is a retrospective study.
We studied 68 consecutive adult patients (28 female, 40 male, age 45.0 +/- 1.8 years; body mass index (BMI): 26.5 +/- 0.6) with intracranial tumors who underwent NS only (n = 17) or in combination with radiotherapy (RT) and/or chemotherapy (CT) (n = 51). In all subjects, basal endocrine parameters and the GH response to GHRH + arginine test (using BMI-dependent cut offs) were evaluated.
In 20.6% of the patients, peripheral endocrinopathy related to CT and/or RT was present. Hypopituitarism was found in 38.2% of the patients. Total pituitary hormone, multiple pituitary hormone, and isolated pituitary hormone deficits were present in 16.2, 5.8, and 16.2% respectively. The most common pituitary deficits were, in decreasing order: LH/FSH 29.4%, GH 27.9%, ACTH 19.1%, TSH 17.7%, and diabetes insipidus 4.4%. Hyperprolactinemia was present in 13.2%. The prevalence of hypopituitarism was higher in patients who underwent NS only and with tumors located closely to the sella turcica, but a substantial proportion of patients with tumors not directly neighboring the sella also showed hypopituitarism.
Hypopituitarism frequently occurs after NS for intracranial tumors. Also, exposure of these patients to CT and/or RT is frequently associated with peripheral endocrinopathies. Thus, endocrine evaluation and follow-up of patients treated for intracranial tumors should be performed on a regular basis.
垂体功能减退常继发于垂体神经外科手术(NS)和/或放疗之后。然而,非垂体颅内肿瘤行NS后下丘脑-垂体功能障碍的发生率尚不清楚。本研究旨在评估颅内肿瘤手术患者内分泌改变的情况。
这是一项回顾性研究。
我们研究了68例连续的成年颅内肿瘤患者(28例女性,40例男性,年龄45.0±1.8岁;体重指数(BMI):26.5±0.6),这些患者仅接受了NS(n = 17)或联合放疗(RT)和/或化疗(CT)(n = 51)。对所有受试者评估基础内分泌参数以及生长激素(GH)对生长激素释放激素(GHRH)+精氨酸试验的反应(使用依赖BMI的临界值)。
20.6%的患者存在与CT和/或RT相关的外周内分泌病变。38.2%的患者发现垂体功能减退。全垂体激素缺乏、多种垂体激素缺乏和单一垂体激素缺乏分别占16.2%、5.8%和16.2%。最常见的垂体激素缺乏依次为:促黄体生成素/促卵泡生成素(LH/FSH)29.4%,GH 27.9%,促肾上腺皮质激素(ACTH)19.1%,促甲状腺激素(TSH)17.7%,尿崩症4.4%。高泌乳素血症占13.2%。仅接受NS且肿瘤紧邻蝶鞍的患者垂体功能减退的发生率更高,但相当一部分肿瘤不直接邻近蝶鞍的患者也出现了垂体功能减退。
颅内肿瘤行NS后垂体功能减退常见。此外,这些患者接受CT和/或RT常伴有外周内分泌病变。因此,应对颅内肿瘤治疗患者定期进行内分泌评估和随访。